Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Oct 12;11(20):3200.
doi: 10.3390/cells11203200.

Biomarker-Targeted Therapies in Non-Small Cell Lung Cancer: Current Status and Perspectives

Haiyang Guo  1   2 , Jun Zhang  1   3 , Chao Qin  1   3 , Hang Yan  1   3 , Tao Liu  1   3 , Haiyang Hu  1   3 , Shengjie Tang  1 , Shoujun Tang  1 , Haining Zhou  1   2   3
Affiliations
Review

Biomarker-Targeted Therapies in Non-Small Cell Lung Cancer: Current Status and Perspectives

Haiyang Guo et al. Cells. .

Abstract

Non-small-cell lung cancer (NSCLC) is one of the most common malignancies and the leading causes of cancer-related death worldwide. Despite many therapeutic advances in the past decade, NSCLC remains an incurable disease for the majority of patients. Molecular targeted therapies and immunotherapies have significantly improved the prognosis of NSCLC. However, the vast majority of advanced NSCLC develop resistance to current therapies and eventually progress. In this review, we discuss current and potential therapies for NSCLC, focusing on targeted therapies and immunotherapies. We highlight the future role of metabolic therapies and combination therapies in NSCLC.

Keywords: immunotherapies; non-small-cell lung cancer; targeted therapies.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
In total, 50–60% of NSCLC cases are adenocarcinomas, whereas 20–30% are squamous cell carcinomas. Adenocarcinoma molecular alterations related to targetable oncogenic drivers. Incidences of oncogenic driver alterations extracted from study results [6,9,10].
Figure 2
Figure 2
Timeline of targeted drugs which FDA approved for oncogene-driven NSCLC.
Figure 3
Figure 3
Current molecular tests for oncogenic drivers.
See this image and copyright information in PMC

References

    1. Siegel R.L., Miller K.D., Fuchs H.E., Jemal A. Cancer statistics, 2022. CA Cancer J. Clin. 2022;72:7–33. doi: 10.3322/caac.21708. - DOI - PubMed
    1. Li M., Meng G.X., Liu X.W., Ma T., Sun G., He H. Deep-LC: A Novel Deep Learning Method of Identifying Non-Small Cell Lung Cancer-Related Genes. Front. Oncol. 2022;12:949546. doi: 10.3389/fonc.2022.949546. - DOI - PMC - PubMed
    1. Soo R., Stone E., Cummings K., Jett J., Field J., Groen H., Mulshine J., Yatabe Y., Bubendorf L., Dacic S., et al. Scientific Advances in Thoracic Oncology 2016. J. Thorac. Oncol. 2017;12:1183–1209. doi: 10.1016/j.jtho.2017.05.019. - DOI - PubMed
    1. Solito S., Marigo I., Pinton L., Damuzzo V., Mandruzzato S., Bronte V. Myeloid-derived suppressor cell heterogeneity in human cancers. Ann. N. Y. Acad. Sci. 2014;1319:47–65. doi: 10.1111/nyas.12469. - DOI - PubMed
    1. Deb D., Moore A.C., Roy U.B. The 2021 Global Lung Cancer Therapy Landscape. J. Thorac. Oncol. 2022;17:931–936. doi: 10.1016/j.jtho.2022.03.018. - DOI - PubMed

Publication types